We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer's Loss Is Competitors' Gain, Analysts Say
Pfizer's Loss Is Competitors' Gain, Analysts Say
December 4, 2006
Pfizer’s sudden decision to end its clinical trials for torcetrapib, a once-likely successor to its blockbuster cholesterol drug Lipitor, not only harms its financial outlook, but also opens the door for other companies to take control of that market, analysts say.